Boehringer Ingelheim and Circle Pharma announce new research collaboration to develop a novel precision cancer treatment Read more
Boehringer receives FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide Read more
Teva and mAbxience Strengthen Strategic Alliance with New Oncology Biosimilar Candidate Addition Read more
FDA Approves Neoadjuvant Opdivo and Chemotherapy for Resectable Non-Small Cell Lung Cancer Treatment Pathway Read more
Boehringer Ingelheim partners with NCD Alliance to target Non-Communicable Diseases in underserved communities Read more
Tagrisso approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer Read more
FDA Approves Merck’s KEYTRUDA (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM) Read more
Amneal and Shilpa Announce FDA Approval of BORUZU, the First Ready-to-Use Version of Bortezomib for subcutaneous administration Read more